You are here

MDX-060 Receives Orphan Drug Designation for Treatment of Hodgkin's Disease

PRINCETON, N.J., Oct. 6 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX - News) today announced that under the U.S. Orphan Drug Act, the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to Medarex's fully human anti-CD30 antibody, MDX-060, for the treatment of Hodgkin's disease. Orphan drug designation is granted to products that treat rare diseases or conditions that affect fewer than 200,000 people in the U.S. Orphan Drug designation provides eligibility for a special seven-year period of market exclusivity at marketing approval, potential tax credits for research, grant funding for research and development, possibly reduced filing fees for marketing applications, and assistance with the review of clinical trial protocols.

"We believe that the MDX-060 has the potential to address a serious unmet medical need, and we expect to continue to rapidly develop this antibody for patients with Hodgkin's disease," said Donald L. Drakeman, President and CEO of Medarex.

About MDX-060
MDX-060 is a fully human antibody that targets CD30, a member of the tumor necrosis factor receptor superfamily and a molecule found on activated lymphocytes. CD30 has been found to be over-expressed in several lymphoproliferative disorders and is present on malignant cells of Hodgkin's disease (HD) and anaplastic large cell lymphoma (ALCL), as well as other CD30- positive lymphomas. Currently, Medarex is conducting an expanded dose-ranging Phase II study with MDX-060 in patients with CD30-positive lymphomas.

Of the nearly 500,000 Americans with lymphoma, 168,000 have HD. According to the American Cancer Society, in 2004 there will be approximately 7,880 new cases of Hodgkin's disease in the United States, and an estimated 1,320 people will die of the disease. The frequency of ALCL in the United States is not known, but worldwide, ALCL accounts for approximately 5% of all non-Hodgkin's lymphoma.

Source: Medarex, Inc.

Recent Headlines

Scenesse is new treatment for people with rare, painful light sensitivity disease
Humira, Rituxan top list of drugs that added $5.1 billion to nation's health care bill
Lower court rulings cleared the way for generic versions of the MS drug
Maryland man wins lawsuit that alleges that the company's antipsychotic caused his gynecomastia
Antidepressants, ADHD meds are also used to self-poison
Descovy joins Truvada, another Gilead product, in the HIV prophylaxis market
Data show PTC Therapeutics drug preserves lung function
U.S. maintains measles elimination status as NY outbreak ebbs
Study lists steps that could save close to $300 billion a year